The overexpression of ERBB2 can be targeted using monoclonal antibodies such as trastuzumab (Herceptin) and pertuzumab (Perjeta). These antibodies bind to the extracellular domain of the ERBB2 protein, inhibiting its signaling and inducing immune-mediated destruction of the cancer cells. Additionally, small molecule inhibitors like lapatinib target the tyrosine kinase domain of ERBB2, further disrupting its signaling pathways.
